Supplements

Modified Sini Powder (MSNP) improves depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression

This protocol describes a multicenter, randomized, double-blind, placebo-controlled trial evaluating MSNP for postoperative depression in NSCLC patients. The primary outcome is a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score after 6 weeks of treatment. The trial aims to provide robust clinical evidence and explore multi-omics mechanisms.

1 min read•Updated Jul 9, 2026•1 RCTs•View structured evidence →
Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Modified Sini Powder (MSNP) improves depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).

The Claim

Modified Sini Powder (MSNP) improves depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression

This conclusion is most relevant to: Postoperative patients with non-small cell lung cancer (NSCLC) and mild-to-moderate depression (n=468, across nine tertiary medical centers).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol. (Frontiers in pharmacology, 2026) —

How It Works

The proposed biological pathway:

  • ▸Inflammatory cytokines modulation
  • ▸Hypothalamic-pituitary-adrenal axis hormone regulation
  • ▸Neurotransmitter and brain-derived neurotrophic factor changes
  • ▸Result: Multi-target and multi-pathway antidepressant effects

Who Might Benefit

Evidence fit by population:

  • ▸Postoperative patients with non-small cell lung cancer (NSCLC) and mild-to-moderate depression (n=468, across nine tertiary medical centers)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸This is a protocol paper; no results are yet available to confirm efficacy or safety.
  • ▸The trial relies on subjective depression rating scales, which may introduce bias despite blinding.
  • ▸Generalizability may be limited to Chinese populations and specific healthcare settings.

Frequently Asked Questions

What is Modified Sini Powder (MSNP)?▼

MSNP is a modified traditional Chinese medicine formula derived from classical Sini Powder, used to alleviate depressive symptoms.

How long is the treatment period in this trial?▼

The intervention lasts for 6 weeks.

What is the primary outcome measure?▼

The primary outcome is the total effective rate, defined as a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score from baseline at the end of treatment.

How many participants are being recruited?▼

468 postoperative NSCLC patients with mild-to-moderate depression will be recruited across nine tertiary medical centers.

References

  1. 1.Jin Y, Wang J, Li H, Fan M, Zhang S, Lin B, Mi Y, Gong C, Gu P, Xu K, Zhao B, Lang J, Chen M. “Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol..” Frontiers in pharmacology, 2026. PMID: 42403716 DOI: 10.3389/fphar.2026.1805554
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.